DSPEPEG2000

DSPEPEG2000 is a synthetic peptide designed to mimic the sequence of the extracellular domain of the human epidermal growth factor receptor 2 (HER2). It is a truncated version of the full-length HER2 extracellular domain, consisting of the first 2000 amino acids. DSPEPEG2000 is conjugated to a polyethylene glycol (PEG) linker and a lipid moiety, which enhances its stability and solubility in aqueous solutions.

The primary application of DSPEPEG2000 is in the field of cancer research and therapy. It is used as a targeting ligand for HER2-positive tumors, which overexpress HER2 on their cell surface. By binding to HER2, DSPEPEG2000 can deliver therapeutic payloads, such as antibodies, toxins, or chemotherapeutics, specifically to HER2-positive cells. This targeted delivery approach aims to improve the efficacy of cancer treatments and reduce off-target effects.

DSPEPEG2000 has been studied in various preclinical models and has shown promise in enhancing the therapeutic index of HER2-targeted therapies. However, its clinical use is still in the early stages of development, and further research is needed to fully understand its safety and efficacy in humans.